- Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. Barron’s
- Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps CNBC
- Novo Nordisk Plunges 20% After Weight-Loss Drug Trial Misses Target Yahoo Finance
- Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg
- A next-gen Ozempic falls short in a drug trial — and Novo Nordisk stock plunges 20% Quartz